Literature DB >> 31048498

Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.

Yi Yang1, Amanda Stang2, Patrick G Schweickert1, Nadia A Lanman1, Erin N Paul1, Brett P Monia3, Alexey S Revenko3, Joseph S Palumbo2, Eric S Mullins2, Bennett D Elzey4, Edith M Janssen5, Stephen F Konieczny6, Matthew J Flick7.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is associated with robust activity of the coagulation system. To determine mechanisms by which clotting factors influence PDAC tumor progression, we generated and characterized C57Bl/6-derived KPC (KRasG12D, TRP53R172H ) cell lines. Tissue factor (TF) and protease-activated receptor-1 (PAR-1) were highly expressed in primary KPC pancreatic lesions and KPC cell lines similar to expression profiles observed in biopsies of patients with PDAC. In allograft studies, tumor growth and metastatic potential were significantly diminished by depletion of TF or Par-1 in cancer cells or by genetic or pharmacologic reduction of the coagulation zymogen prothrombin in mice. Notably, PAR-1-deleted KPC cells (KPC-Par-1KO) failed to generate sizable tumors, a phenotype completely rescued by restoration of Par-1 expression. Expression profiling of KPC and KPC-Par-1KO cells indicated that thrombin-PAR-1 signaling significantly altered immune regulation pathways. Accordingly, KPC-Par-1KO cells failed to form tumors in immune-competent mice but displayed robust tumor growth comparable to that observed with control KPC cells in immune-compromised NSG mice. Immune cell depletion studies indicated that CD8 T cells, but not CD4 cells or natural killer cells, mediated elimination of KPC-Par-1KO tumor cells in C57Bl/6 mice. These results demonstrate that PDAC is driven by activation of the coagulation system through tumor cell-derived TF, circulating prothrombin, and tumor cell-derived PAR-1 and further indicate that one key mechanism of thrombin/PAR-1-mediated tumor growth is suppression of antitumor immunity in the tumor microenvironment. SIGNIFICANCE: The tissue factor-thrombin-PAR-1 signaling axis in tumor cells promotes PDAC growth and disease progression with one key mechanism being suppression of antitumor immunity in the microenvironment. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31048498      PMCID: PMC6699516          DOI: 10.1158/0008-5472.CAN-18-3206

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  A high-capacity quantitative mouse model of drug-mediated immunosuppression based on rejection of an allogeneic subcutaneous tumor.

Authors:  D Hammond-McKibben; P Lake; J Zhang; N Tart-Risher; R Hugo; M Weetall
Journal:  J Pharmacol Exp Ther       Date:  2001-06       Impact factor: 4.030

2.  Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/mitogen-activated protein kinase pathway.

Authors:  C A Ellis; A B Malik; A Gilchrist; H Hamm; R Sandoval; T Voyno-Yasenetskaya; C Tiruppathi
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

3.  Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin.

Authors:  S C Even-Ram; M Maoz; E Pokroy; R Reich; B Z Katz; P Gutwein; P Altevogt; R Bar-Shavit
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

4.  Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells.

Authors:  X Jiang; M A Bailly; T S Panetti; M Cappello; W H Konigsberg; M E Bromberg
Journal:  J Thromb Haemost       Date:  2004-01       Impact factor: 5.824

5.  Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1.

Authors:  C Rudroff; S Striegler; M Schilli; J Scheele
Journal:  Eur J Surg Oncol       Date:  2001-08       Impact factor: 4.424

6.  Regulation of angiogenesis by tissue factor cytoplasmic domain signaling.

Authors:  Mattias Belting; Michael I Dorrell; Staffan Sandgren; Edith Aguilar; Jasimuddin Ahamed; Andrea Dorfleutner; Peter Carmeliet; Barbara M Mueller; Martin Friedlander; Wolfram Ruf
Journal:  Nat Med       Date:  2004-04-18       Impact factor: 53.440

7.  Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis.

Authors:  B M Mueller; R A Reisfeld; T S Edgington; W Ruf
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

Review 8.  Antitumor and antimetastatic effect of warfarin and heparins.

Authors:  Vladimir Bobek; Josef Kovarík
Journal:  Biomed Pharmacother       Date:  2004-05       Impact factor: 6.529

9.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

Authors:  Sunil R Hingorani; Emanuel F Petricoin; Anirban Maitra; Vinodh Rajapakse; Catrina King; Michael A Jacobetz; Sally Ross; Thomas P Conrads; Timothy D Veenstra; Ben A Hitt; Yoshiya Kawaguchi; Don Johann; Lance A Liotta; Howard C Crawford; Mary E Putt; Tyler Jacks; Christopher V E Wright; Ralph H Hruban; Andrew M Lowy; David A Tuveson
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

10.  Tumor rejection by disturbing tumor stroma cell interactions.

Authors:  S Ibe; Z Qin; T Schüler; S Preiss; T Blankenstein
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  18 in total

1.  A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma.

Authors:  Michael J Bradney; Stephanie M Venis; Yi Yang; Stephen F Konieczny; Bumsoo Han
Journal:  Small       Date:  2020-01-30       Impact factor: 13.281

2.  Rivaroxaban does not affect growth of human pancreatic tumors in mice.

Authors:  Anaum Maqsood; Yohei Hisada; Kenison B Garratt; Jonathon Homeister; Nigel Mackman
Journal:  J Thromb Haemost       Date:  2019-08-26       Impact factor: 5.824

Review 3.  Tissue factor: a neglected role in cancer biology.

Authors:  Haiyuan Li; Yang Yu; Lei Gao; Peng Zheng; Xiaolong Liu; Hao Chen
Journal:  J Thromb Thrombolysis       Date:  2022-06-28       Impact factor: 2.300

4.  Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis.

Authors:  Thita Chiasakul; Robert Redd; Rushad Patell; Adeel M Khan; Ellen P McCarthy; Donna Neuberg; Jeffrey I Zwicker
Journal:  J Thromb Haemost       Date:  2021-09-21       Impact factor: 5.824

Review 5.  GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.

Authors:  Krishna Sriram; Cristina Salmerón; Shu Z Wiley; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

Review 6.  Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype.

Authors:  Abigail C Cornwell; Michael E Feigin
Journal:  Trends Pharmacol Sci       Date:  2020-10-22       Impact factor: 14.819

7.  Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment.

Authors:  Patrick G Schweickert; Yi Yang; Emily E White; Gregory M Cresswell; Bennett D Elzey; Timothy L Ratliff; Paritha Arumugam; Silvio Antoniak; Nigel Mackman; Matthew J Flick; Stephen F Konieczny
Journal:  J Thromb Haemost       Date:  2020-10-25       Impact factor: 5.824

Review 8.  Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma.

Authors:  Aditi Kothari; Matthew J Flick
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 6.208

9.  Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.

Authors:  Axel Rosell; Bernhard Moser; Yohei Hisada; Rukesh Chinthapatla; Grace Lian; Yi Yang; Matthew J Flick; Nigel Mackman
Journal:  Res Pract Thromb Haemost       Date:  2020-07-06

10.  Combined inhibition of Ref-1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour co-culture models.

Authors:  Rachel A Caston; Fenil Shah; Colton L Starcher; Randall Wireman; Olivia Babb; Michelle Grimard; Jack McGeown; Lee Armstrong; Yan Tong; Roberto Pili; Joseph Rupert; Teresa A Zimmers; Adily N Elmi; Karen E Pollok; Edward A Motea; Mark R Kelley; Melissa L Fishel
Journal:  J Cell Mol Med       Date:  2020-12-03       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.